AML-related mutations
ASXL1
CEBPA
DNMT3A
EZH2
FLT3-ITD
FLT3-TKD
GATA2
IDH1
IDH2
KIT
KRAS
NF1
NPM1
NRAS
PTPN11
RAD21
RUNX1
SF3B1
SMC1A
SMC3
SRSF2
STAG1
STAG2
TET2
TP53
U2AF1
WT1
ZRSR2
Chromosomal aberrations
BCR-ABL1
CBFB-MYH11
Core binding factor
KMT2A rearranged
MLLT3-KMT2A
Myelodysplasia-related
Disease
De novo
Newly diagnosed
Promyelocytic leukemia
Relapsed/refractory
Secondary
Therapy-related
Risk
COVID-19
Favorable-risk
High-risk
Intermediate-risk